Valneva sees lower 2026 sales as third-party revenue winds down
Source: SeekingAlpha
2026-02-19 05:13:43 ET
More on Valneva
- Valneva chikungunya shot no longer recommended for older adults in U.K.
- Valneva ends chikungunya vaccine deal with India’s Serum Institute
- Seeking Alpha’s Quant Rating on Valneva
- Historical earnings data for Valneva
- Financial information for Valneva
Read the full article on Seeking Alpha
For further details see:
Valneva sees lower 2026 sales as third-party revenue winds down
Valneva SE
NASDAQ: VALN
VALN Trading
-2.97% G/L:
$10.61 Last:
3,909 Volume:
$10.53 Open:
VALN Latest News
October 01, 2025 04:20:00 pm
Ongoing Valneva SE (VALN) Investigation: Protect Your Rights - Contact Levi & Korsinsky
VALN Stock Data
$798,793,290
73,508,485
N/A
10
N/A
Biotechnology & Life Sciences
Healthcare
FR
Lyon
